Strategic Partnerships GenomeScan collaborates closely with major clinical centers (Erasmus MC and Leiden University Medical Center) and partners with pharmaceutical and biotechnology companies to advance diagnostics and patient care, indicating opportunities for joint development projects, data collaborations, and contract research.

Clinical-Grade Capabilities With ISO/IEC 17025 accreditation, GCLP and GLP compliance, and an in-house lab capable of rapid genetic profiling in 48 hours, GenomeScan offers trusted, scalable testing services suitable for large clinical and preclinical studies, ideal for enterprise contracting and service-level agreements.

NGS & Beyond Service portfolio spans whole exome sequencing, panel sequencing, transcriptomics, and epigenetics, paired with advanced bioinformatics pipelines, signaling cross-sell opportunities into multi-omics projects for pharma, biotech, and clinical research organizations.

High-Throughput Readiness Investment in industry-scale sequencers (NovaSeq 6000, PacBio Sequel), robotics, and robust IT infrastructure positions GenomeScan to handle large-scale studies and high-throughput proteomics-driven collaborations, appealing to partners seeking scalable analytics capabilities.

Growth via Alliances Recent partners and events, such as a 2023 proteomics collaboration with Olink and participation in Swiss Biotech Day, indicate a momentum-driven expansion strategy; target outreach to potential industry partners and contract opportunities aligned with proteomics, diagnostics, and precision medicine.